Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ad-RTS-hIL-12 · INXN-2001

Gene therapy (Adenoviral vector) · Gene-mediated cytotoxicity · developed by Alaunos Therapeutics

Phase 1/2 Most advanced trial (none active)

TCRT Developer

2 Registered trials

What is Ad-RTS-hIL-12?

Ad-RTS-hIL-12 is an adenoviral vector encoding human interleukin-12 under control of an inducible RheoSwitch system activated by veledimex. Upon intratumoral injection with veledimex, it expresses IL-12 to activate natural killer cells and cytotoxic T-lymphocytes against tumor cells. It is studied in melanoma and metastatic breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: INXN-2001
Drug type: Gene therapy (Adenoviral vector)
Mechanism: Gene-mediated cytotoxicity
Pathways: immune activation, interferon-gamma secretion, natural killer cell activation, cytotoxic T-lymphocyte response
Therapy area: Oncology
Developer: Alaunos Therapeutics (TCRT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02423902	Phase 1/2	Metastatic Breast Cancer	Terminated	TCRT
NCT01397708	Phase 1/2	Melanoma	Completed	TCRT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MelanomaMetastatic Breast Cancer

More from Alaunos Therapeutics

Darinaparsin Phase 2 Indibulin Phase 1/2 INXN-3001 Phase 1 Palifosfamide Phase 3 Veledimex Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the TCRT page.

Follow TCRT, the company behind Ad-RTS-hIL-12

See TCRT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TCRT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z